Diabetic Macular Oedema Guidelines: An Australian Perspective

Area of Science:

• Ophthalmology
• Endocrinology
• Public Health

Background:

• Diabetes prevalence is increasing globally, leading to a rise in ocular complications such as diabetic retinopathy (DR) and diabetic macular edema (DMO).
• Diabetic retinopathy affects a significant portion of individuals with diabetes, with some forms posing a serious threat to vision.
• DR is a leading cause of vision loss in working-age adults in many countries, including Australia.

Purpose of the Study:

• To review and update the management strategies for diabetic macular edema (DMO) in Australia.
• To address recent advancements in DMO treatment options and schedules since the 2008 NHMRC guidelines.

Main Methods:

• Review of current literature and treatment guidelines for diabetic macular edema.
• Analysis of recent developments in antivascular endothelial growth factor (VEGF) and corticosteroid therapies.
• Evaluation of treatment schedules and their efficacy in managing DMO.

Main Results:

• Focal/grid laser photocoagulation can reduce visual loss in DMO by 50% or more.
• Anti-VEGF and corticosteroid therapies have emerged as effective alternatives to laser treatment, offering better visual improvement potential.
• Significant developments in DMO treatment options and schedules have occurred in Australia since 2008.

Conclusions:

• Current management of DMO in Australia has evolved beyond traditional laser photocoagulation.
• Anti-VEGF and corticosteroid therapies represent significant advancements in improving vision for patients with DMO.
• Ongoing review and adaptation of treatment guidelines are essential to address the growing burden of diabetic eye disease.